Literature DB >> 15574780

Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung cancer.

Carmen J Marsit1, Masayuki Hasegawa, Tomoko Hirao, Duk-Hwan Kim, Kenneth Aldape, Philip W Hinds, John K Wiencke, Heather H Nelson, Karl T Kelsey.   

Abstract

Allelic loss of chromosome region 3p21.3 occurs early and frequently in non-small-cell lung cancer, and numerous tumor suppressor genes at this locus may be targets of inactivation. Using an incident case series study of non-small-cell lung cancer, we sought to determine the prevalence of loss of heterozygosity (LOH) in the 3p21.3 region and to examine the associations between this alteration and patient outcome, exposure to tobacco smoke, occupational asbestos exposure, and additional molecular alterations in these tumors. We examined LOH at 7 microsatellite markers in the chromosome 3p21.3 region, and LOH was present in at least one of the loci examined in 60% (156 of 258) of the tumors, with the prevalence of LOH at individual loci ranging from 15 to 56%. Occupational asbestos exposure and TP53 mutation were significantly associated with more extensive 3p21 LOH. In squamous cell carcinomas, measures of cumulative smoking dose were significantly lower in patients with LOH at 3p21, particularly in TP53 mutant tumors. Examining patient outcome, we found that in squamous cell carcinomas, having any LOH in this region was associated with a better overall survival (log-rank test, P < 0.04). Together, these results indicate that allelic loss at 3p21 can affect patient outcome, and that this loss may initially be related to carcinogen exposure, but that extension of this loss is related to TP53 mutation status and occupational asbestos exposure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15574780     DOI: 10.1158/0008-5472.CAN-04-2558

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos.

Authors:  Brooke T Mossman; Morton Lippmann; Thomas W Hesterberg; Karl T Kelsey; Aaron Barchowsky; James C Bonner
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

2.  Loss of heterozygosity of the tumor suppressor gene Tg737 in the side population cells of hepatocellular carcinomas is associated with poor prognosis.

Authors:  Zhi Song; Ren Li; Nan You; Kaishan Tao; Kefeng Dou
Journal:  Mol Biol Rep       Date:  2010-03-19       Impact factor: 2.316

3.  Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos-exposed patients.

Authors:  Penny Nymark; Mervi Aavikko; Jussi Mäkilä; Salla Ruosaari; Tuija Hienonen-Kempas; Harriet Wikman; Kaisa Salmenkivi; Risto Pirinen; Antti Karjalainen; Esa Vanhala; Eeva Kuosma; Sisko Anttila; Eeva Kettunen
Journal:  Mol Oncol       Date:  2012-08-07       Impact factor: 6.603

4.  Genetic and epigenetic tumor suppressor gene silencing are distinct molecular phenotypes driven by growth promoting mutations in nonsmall cell lung cancer.

Authors:  Carmen J Marsit; E Andres Houseman; Heather H Nelson; Karl T Kelsey
Journal:  J Cancer Epidemiol       Date:  2009-01-28

Review 5.  Hyalurondiase: both a tumor promoter and suppressor.

Authors:  Vinata B Lokeshwar; Marie G Selzer
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

Review 6.  Hyaluronan and hyaluronidase in genitourinary tumors.

Authors:  Melanie A Simpson; Vinata B Lokeshwar
Journal:  Front Biosci       Date:  2008-05-01

7.  Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.

Authors:  Paula Lázcoz; Jorge Muñoz; Manuel Nistal; Angel Pestaña; Ignacio Encío; Javier S Castresana
Journal:  BMC Cancer       Date:  2006-10-25       Impact factor: 4.430

8.  Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines.

Authors:  Penny Nymark; Pamela M Lindholm; Mikko V Korpela; Leo Lahti; Salla Ruosaari; Samuel Kaski; Jaakko Hollmén; Sisko Anttila; Vuokko L Kinnula; Sakari Knuutila
Journal:  BMC Genomics       Date:  2007-03-01       Impact factor: 3.969

9.  Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

Authors:  A Kalikaki; A Koutsopoulos; M Trypaki; J Souglakos; E Stathopoulos; V Georgoulias; D Mavroudis; A Voutsina
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

10.  Pathways affected by asbestos exposure in normal and tumour tissue of lung cancer patients.

Authors:  Salla Ruosaari; Tuija Hienonen-Kempas; Anne Puustinen; Virinder K Sarhadi; Jaakko Hollmén; Sakari Knuutila; Juha Saharinen; Harriet Wikman; Sisko Anttila
Journal:  BMC Med Genomics       Date:  2008-11-11       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.